Market Place
Sourcing Support
Paradigm says PhII trial in osteoarthritis shows signs of disease modification
11 Apr 2023 //
GLOBENEWSWIRE
Paradigm debuts with $203M series A funding
31 Jan 2023 //
FIERCE BIOTECH
Paradigm Achieves Primary Endpoint in PARA_OA_008 PII Trial
04 Oct 2022 //
PRNEWSWIRE
Paradigm Partners with NFL Alumni Health on Osteoarthritis Program
14 Jul 2022 //
PRNEWSWIRE
Paradigm Bio begins UK-based screening for PIII study assessing Zilosul
06 Jul 2022 //
PROACTIVEINVESTORS
Paradigm Biopharmaceuticals Appoints Marco Polizzi As Chief Executive Officer
27 Jun 2022 //
PRNEWSWIRE
Paradigm Biopharma Retains Rubenstein Public Relations as Agency of Record
19 Apr 2022 //
PRNEWSWIRE
FDA Grants FTD for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
13 Apr 2022 //
PRNEWSWIRE
Paradigm BioPharma Initiates a P 3 Trial in Knee Osteoarthritis Across the U.S
17 Mar 2022 //
PRNEWSWIRE
Paradigm Biopharmaceuticals releases positive top-line preclinical study results
13 Oct 2021 //
PROACTIVEINVESTORS
Paradigm Biopharmaceuticals receives US FDA feedback on IND for PPS in knee OA
25 May 2021 //
PROACTIVEINVESTORS
Paradigm Receives positive feedback on Zilosul® from EMA
27 Sep 2020 //
PROACTIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.